Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05074719 Completed - COVID-19 Clinical Trials

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

IICov19PRS
Start date: December 10, 2020
Phase:
Study type: Observational

Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are underway under separate protocol(s) for close contacts (i.e., household contacts, [e.g.,3502]) of infectious (index) individuals (3502-01). Characterizing the index individuals within households will ascertain the risk of exposure for the contact participant. These data will be used to strengthen the precision of efficacy estimates. This ancillary observational study will assess the cofactors for infectiousness among index individuals whose close contacts are enrolled in COVID-19 prevention clinical trials. Additionally, this study will assess post-acute sequelae of SARS-CoV-2 infection in index individuals that are more than two weeks past their initial diagnosis.

NCT ID: NCT05074446 Completed - COVID-19 Clinical Trials

Stereotype Threat Effect on CPR Performance in Covid-19 Intensive Care Units: A Randomised Controlled Mannequin Study

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

Stereotype threat (ST) is an important issue that has been studied repeatedly in the psychology literature. ST is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs. Most people are members of a social group associated with at least one negative stereotype. Therefore, many people in society may be the target of stereotype threat. Previous research has shown that the individual performance of people in groups identified with negative stereotypes, who are exposed to stereotype threat, decreases. The ST may arise when there is an environment in which the skills of the person that may be affected by a stereotype associated with his/her group can be measured, or if this stereotype has become evident. In Covid-19, there has been a rapid increase in the number of intensive care patients in our country and around the World. Due to this rapid increase, the number of intensivist physicians is insufficient, and non-intensivist physicians from various branches are assigned to intensive care units. In social media and newspaper reports, it was stated that non-intensivist physicians have insufficient knowledge and skills in intubation and in the treatment of lung infection, and the public was asked to take precautions. However, these physicians were expected to treat lung infections and intubate the patients in intensive care units during pandemics. It is unknown to what extent such negative stereotypes, established or already existing, affect the performance of non-intensivist physicians during their appointment to the intensive care units during the pandemic. As in all other departments, the most basic task expected from doctors in intensive care units is effective basic life support applied for the treatment of cardiopulmonary arrest. Cardiopulmonary resuscitation (CPR) is a basic life support model that is mandatory taught in medical schools. For this reason, it is expected that all doctors, regardless of their specialties, will be able to perform CPR effectively. The use of manikins is quite common in order to standardize CPR training and performance measurement. The aim of this study is to evaluate how non-intensivist physicians assigned to intensive care units during the pandemic are affected by stereotype threat and to investigate the necessary conditions to prevent a possible decrease in performance in these physicians.

NCT ID: NCT05074407 Completed - Neck Pain Clinical Trials

Neck Pain in Office Workers During Covid 19 Pandemic

Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

Work content of office workers are using computers, conferences, presentations and talking on the phones. Static postures and repetitive writing and reading activities at inappropriate body postures are the most common activities of office workers. Decreased physical activity and prolonged computer use cause occupational safety problems and musculoskeletal problems. Neck pain is one of the most common problem in office workers and the studies have shown the incidence of neck pain in office workers is 34-49% . The aim of this study to evaluate the effects of remote employee in neck pain in Office workers during covid 19 pandemic

NCT ID: NCT05074017 Completed - COVID-19 Clinical Trials

COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests

COVAG
Start date: February 1, 2021
Phase:
Study type: Observational

The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche & Abbott). The study will be performed at the Corona Test Center Stuttgart Cannstatter Wasen. Approximately 2000 patients will be enrolled after having signed the Informed Consent Form (ICF). Each patient will receive 3 nasopharyngeal swabs. Two for the rapid antigen tests from Roche and Abbott and one for the RT-PCR. Furthermore an anamnesis, short clinical examination and blood draw is done. The blood is examined for SARS-CoV-2 antibodies and basic laboratory tests to be communicated to participants.

NCT ID: NCT05072496 Completed - COVID-19 Clinical Trials

Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine

Start date: July 20, 2020
Phase:
Study type: Observational

The study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received COVID-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old. Every participant was familiarized with the aim of the study and asked to sign an informed consent agreement, and be required blood sampling at the day 0 of first dose vaccine and 1 month, 3 months, 6 months and 12 months after fully vaccination separately. From every sample, 10 ml, 10 ml, and 5 ml were dispensed in three vacuum blood collection tubes. Peripheral blood lymphocytes cell (PBMC) were isolated with the two 10 ml samples contained heparin to detect immune memory cells and cytokines. RBD-IgG and neutralizing antibody be detected by 5ml sample from separating gel vacuum tubes. every individual conducted a detailed analysis comparing neutralizing antibody, TEM, TCM , and report on the cellular and humoral immunity 1 year after accept COVID-19 vaccine.

NCT ID: NCT05070091 Completed - COVID-19 Clinical Trials

The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.

ENDO-COVID19
Start date: January 26, 2021
Phase:
Study type: Observational

The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.

NCT ID: NCT05069662 Completed - Cancer Clinical Trials

Impact of the COVID-19 Pandemic on Drug Use and Monitoring of Cancer Patients

ONCORAL-Covid
Start date: October 5, 2021
Phase:
Study type: Observational

The COVID-19 pandemic has profoundly changed the organisation of care. Teleconsultation has replaced hospital medical consultations in order to reduce the risk of patient exposure to the virus. Within the framework of the Oncoral multidisciplinary outpatient / hospital program of follow-up, carried out by the Hospices Civils de Lyon for ambulatory patients treated with oral anticancer drugs, interviews with the pharmacist and/or nurse, which were previously organised face-to-face, have been replaced by telephone interviews, ensuring continuity of follow-up for patients without having to come to the hospital. This study focuses on a telephone survey to describe the impact of the COVID-19 pandemic health crisis on the drug exposure of cancer patients followed in the Oncoral program, their treatment management, their perception of teleconsultation and their IT resources for remote monitoring.

NCT ID: NCT05069649 Completed - Clinical trials for Immunization Against COVID-19

Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2

Start date: October 6, 2021
Phase: Phase 3
Study type: Interventional

The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in individuals vaccinated against a new coronavirus infection (SARS-CoV-2)

NCT ID: NCT05069623 Completed - COVID-19 Clinical Trials

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). tThree dose levels will be tested. IM administrations 21 days apart. Part 1 is a dose escalation phase and Part 2 is a dose expansion phase. In Part 2 a selected dose will be tested further in additional healty volunteers.

NCT ID: NCT05069610 Completed - COVID-19 Clinical Trials

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

Start date: March 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could potentially be an effective treatment for SARS-CoV-2 infection. This Phase 2a, multi-center study is set up to assess the safety, tolerability, and potential efficacy of AD17002 in participants with mild to moderate COVID-19. The Immunogenicity of repeated doses of AD17002 will also be explored.